ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY

Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021

28 Jul 2021 08:11:31 By Nasdaq GlobeNewswire

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

19 May 2021 17:00:00 By Nasdaq GlobeNewswire

First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model

11 May 2021 08:00:02 By Nasdaq GlobeNewswire

Adaptimmune Reports First Quarter Financial Results and Business Update

06 May 2021 07:30:01 By Nasdaq GlobeNewswire

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

27 Apr 2021 16:30:00 By Nasdaq GlobeNewswire

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

22 Apr 2021 08:00:02 By Nasdaq GlobeNewswire

Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

25 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

11 Feb 2021 08:00:02 By Nasdaq GlobeNewswire